Open Call for Vaccine Development Services
The European Commission Research and Innovation Directorate published a report it had commissioned to evaluate the role and impact of the European Union’s (EU) Research Framework Programme activities in the field of Poverty-Related and Neglected Diseases (PRNDs).
VAC2VAC is pleased to announce that one year after its start it has already created enough interest to have the Medicines Evaluation Board (MEB), a regulatory agency and an independent administrative body residing under the Government of the Netherlands, joining its membership.
During the first year of the VAC2VAC project ample of process has been made. Here you can find a two page summary of the progress.
The European Commission (EC), in the context of the Horizon 2020 Framework Programme, commits significant funding to TRANSVAC2, a European vaccine research and development (R&D) infrastructure.
“Four years of European research on the development of universal influenza vaccines: what have we learnt, and how can we move forward?”
The EDUFLUVAC partners, as part of their work programme on the development of a broadly reactive influenza vaccine, are planning a workshop in close collaboration with the FLUTCORE and UNISEC consortia entitled: “Four years of European research on the development of universal influenza vaccines: what have we learnt and how can we move forward?”.
The workshop will be held in Brussels, Belgium on 12-14 June 2017
World Malaria Day is a chance to shine a spotlight on the global effort to control malaria. Each year on April 25, Roll Back Malaria (RBM) partner organizations unite around a common World Malaria Day theme.